A Day of Reckoning for Aging Facilities: Is It Time to Invest in Change?

With its acquisition of Hospira, Pfizer joins the ranks of pharmaceutical companies struggling to eke out a profit from aging sterile injectables facilities without shutting them down for badly needed upgrades for fear of triggering additional drug shortages. Meanwhile, flexible, modular next-generation facilities that could add capacity where needed are on the horizon.